drugset / Trial / NCT03640754
A Study of the Safety and Effect of Repeated Administration of G-CSF on Hot Flashes in Postmenopausal Women
Phase 1
Completed
61 enrolled
MenoGeniX, Inc.
National Institute on Aging (NIA) · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to assess the efficacy and safety of repeated administration of G-CSF for the treatment of hot flashes and vasomotor symptoms in women with naturally-occurring or surgically induced menopause. G-CSF will be administered three times at 28 day intervals to postmenopausal women, ages 40 to 65, suffering at least 49 moderate to severe hot flashes per week.
Timeline
- Start
- 2018-08-06
- Primary completion
- 2022-01-21
- Completion
- 2022-02-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | G-CSF | Unknown | 1 ml | Subcutaneous |
Indications
No indication recorded.